Evidence map›Paper›PMID 41078357›Full record

ArticleFrontiers in cellular and infection microbiology2025

Global epidemiology and resistance-related mutations of ceftazidime-avibactam-resistant

Xinya Xie, Jiali Chen, Lihua Qi, Yue Yuan, Jiamin Long, Xuelian Wu, Yuan Liu, Jinpeng Guo, Changjun Wang, Xiangzhao Meng and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Repeated emergence and fitness heterogeneity of KPC-33 in ST11Antimicrobial agents and chemotherapy · 2026
    Article
  2. Carbapenem-ResistantMicroorganisms · 2026
    Review
  3. Targeting KPC-ProducingMicroorganisms · 2026
    Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xinya Xie *School of Public Health, China Medical University, Shenyang, China.
Jiali Chen *School of Medicine, NanKai University, Tianjin, China.
Lihua Qi *Department of Laboratory, The Seventh Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Yue Yuan *Department of Disease Control and Prevention, The Fifth Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Jiamin LongSchool of Public Health, China Medical University, Shenyang, China.
Xuelian WuSchool of Public Health, China Medical University, Shenyang, China.
Yuan LiuSchool of Public Health, China Medical University, Shenyang, China.
Jinpeng GuoChinese People's Liberation Army (PLA) Center for Disease Control and Prevention, Beijing, China.
Changjun WangChinese People's Liberation Army (PLA) Center for Disease Control and Prevention, Beijing, China.
Xiangzhao MengDepartment of Laboratory, Beijing Aerospace General Hospital, Beijing, China.
Xiong LiuChinese People's Liberation Army (PLA) Center for Disease Control and Prevention, Beijing, China.
Yong ChenSchool of Public Health, China Medical University, Shenyang, China.
Jie LiuDepartment of Laboratory, The Seventh Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Carbapenem-resistant Methods: Non-repetitive Results: A total of 301 CAZ/AVI-R Conclusion: The combination of multiple drug resistance-related mutations leads to resistance to CAZ/AVI. The most common resistance-related mutations in strains from both public databases and those collected by our team are the coexistence of outer membrane porins and efflux pump mutations, and carriage of MBLs genes.

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsCeftazidimeDrug Resistance, Multiple, BacterialKlebsiella InfectionsKlebsiella pneumoniaeBacterial ProteinsDrug CombinationsGenome, BacterialHumansMicrobial Sensitivity TestsMolecular EpidemiologyMutationSerogroupSewageVirulence FactorsAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsBacterial ProteinsCeftazidimeDrug CombinationsSewageVirulence Factorsceftazidime-avibactam resistancegenome analysisKlebsiella pneumoniaeouter membrane porinsresistance-related mutations

Identifiers

PMID41078357
PMCPMC12507769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.